乙基2-氯-4,6-二羟基烟酸 | 70180-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 乙基2-氯-4,6-二羟基烟酸
• 英文名称: 2-Chlor-4,6-dihydroxy-3-ethoxycarbonyl-pyridin
• 英文别名: Ethyl 2-Chloro-4,6-dihydroxynicotinate；ethyl 2-chloro-4-hydroxy-6-oxo-1H-pyridine-3-carboxylate
• CAS: 70180-38-0
• 化学式: C₈H₈ClNO₄
• 分子量: 217.609
• InChiKey: XAMKYZWQQAAKRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Pyridinone and pyridinethione derivatives having hiv inhibiting properties
  申请人：——

  公开号：US20040229847A1

  公开（公告）日：2004-11-18

  The present invention is concerned among others with compounds of formula (I), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein Q is halo, C 1-6 alkyl or C 2-6 alkenyl; X is (a-2) with q and r being O and Z being O, S or SO; R 1 is aryl; R 2 is selected from formyl; C 1-6 alkyloxycarbonylalkyl; Het 2 ; Het 2 C 1-6 alkyl, C 1-6 alkylthio; C 1-6 alkyl optionally substituted with one or two substituents each independently selected from hydroxy, and halo; R 3 is selected from formyl; C 1-6 alkyl optionally substituted with one or two C 1-6 alkyloxy; R 1 is hydrogen, with HTV inhibiting properties. 1

  本发明涉及式(I)的化合物，其N-氧化物，药学上可接受的加成盐，季铵盐和立体化学异构体形式，其中Q是卤素，C1-6烷基或C2-6烯基; X为(a-2)，其中q和r为O，Z为O，S或SO; R1为芳基; R2选自甲酰基; C1-6烷氧羰基烷基; Het2; Het2C1-6烷基，C1-6烷基硫醚; C1-6烷基，可选用一个或两个取代基，独立地选自羟基和卤素; R3选自甲酰基; C1-6烷基，可选用一个或两个C1-6烷氧基; R1为氢，具有HTV抑制性能。
• PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES
  申请人：CENTRE NATIONAL DELA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：EP1318995A2

  公开（公告）日：2003-06-18
• US7115608B2
  申请人：——

  公开号：US7115608B2

  公开（公告）日：2006-10-03
• [EN] PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES<br/>[FR] DERIVES DE PYRIDINONE ET DE PYRIDINETHIONE PRESENTANT DES PROPRIETES INHIBITRICES DU VIH
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2002024650A2

  公开（公告）日：2002-03-28

  The present invention is concerned among others with compounds of formula (1), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein Q is halo, C1-6 alkyl or C2-6 alkenyl; X is (a-2) with q and r being O and Z being O, S or SO; R1 is aryl; R2 is selected from formyl; C1-6alkyloxycarbonylalkyl; Het?2; Het2C¿1-6alkyl, C1-6alkylthio; C1-6alkyl optionally substituted with one or two substituents each independently selected from hydroxy, and halo; R3 is selected from formyl; C1-6alkyl optionally substituted with one or two C1-6alkyloxy; R4 is hydrogen, with HIV inhibiting properties.